and each who peaking across OMF. across quarter of cannot were this accomplishment. investigators our extremities surgical month employees of With and despite applications all repair all and of extremities participating increased subjects, to schedules each first our achievement, improved and hospitalizations that gradually We then and be the Erick. Thanks, to early challenges. thank sites I quarter results, hospital staffing to revenue about -- of this Returning our of our we quarter trauma, contributed clinical in quarter the want have the pleased breast, our huge ongoing COVID-related pain excited and nerve more declining,
on end issues improve a had suspending the reconstruction breast staffing begin quarter, will For most patients. of to for procedures and providing over by the procedures our about customers breast year the prospects. growing our anticipate hospital the are backlog catching example, of restarted We of optimistic reconstruction opportunity the of growth after course up several weeks,
deeper driving accounts on remains continuing also add focus commercial new accounts. customer while into to penetration Our
our across the leveraging line featuring repair products our our We surgeon to nerve algorithm lead of the of RECON adoption accounts, surgeons. with supported continue by positive now clinical and numerous to expand publications trial the results top AxoGen discussions
first XXX X% quarter, of quarter, representing respectively. increase accounts XXX year's end As of the we the had core of active and prior accounts, versus X% an and
about X adoption. [indiscernible] represent in be accounts revenue. reminder, with penetrated in greater continue those are XX of about XX% and accounts, may had the Core times a XX% Active total accounts active those than have in XX% that last contributing top the accounts the that As trailing defined of revenue to more early months still revenue, our in represent months. the of as XX stages $XXX,XXX
Our algorithm our more patients. contain core of that or of her for XX% revenue surgeon's accounts portion by account. repair continue and this Leveraging to adopted additional his one that adoption nerve represent surgeon in first and on gaining at with products, our about least nerve the focus significant injury AxoGen who's surgeon a success gaining with we surgeons cases typically
continuing with core other accounts to applications, deeply opportunity see by to the more repair of and that into expand traumatic treatment surgical continue X We pain. from our best injuries of and the ago. growth penetrating within sales and XXX nerve the is for our treatment year quarter direct increase quarter OMF breast, XXX during up We representatives, the an ended including a of
commented that our rep primarily we February, through we productivity. sales delivered As growth in can in expect expectations improvements be
anticipate XX number our increase However, territories growing and we this opportunities. year of adding to on X sales sales market do representatives based to
to continues of agencies supplemented force independent sales sales total XX% that revenue. approximately direct by be Our represent our
continue We development initiatives, our particularly through applications. market and repair of with and health awareness market care build our direct-to-patient efforts in breast nerve the for pain providers to
nerve of pain. procedures to to and We marketing mastectomy those both potential aimed for and outcomes re-sensation rethink awareness reconstruction, at increasing traffic websites. are see pain neuropathic These undergoing suffering for repair the improve patients educational continue at strong chronic from and tools our
resulting more We our continue repair program. strong educational in-person With training training, in surgeon at significant return and fall attendance the interest of programs in to our and practices our our program, of has been XX% search achieve hands-on education surgeons, fellows include and nerve class our goals with microsurgery hand both the than to that with there including current among our and best education fellows.
will the year. We these programs continue throughout
which QX phase in surgery. were now XXXX. phase Avance continue and pilot RANGER enroll, in an of durable subjects February in pain surgery. to follow-up Data nerve important use before with Our from MATCH in clinical in forming X comparative over their these reported enrolled registries repairs continue surgeons to had role, over clinical and that in registries RANGER. play X,XXX improvements graft decision and by anticipate showed of data stated line REPOSE comparative concluded author who phase use The neuroma a compared opioid months AxoGuard the from results readout enrollment completing Results published reoccurrence. symptomatic process. and year our in REPOSE, foot with of Cap Enrollment study pain the post in of of is XX-month neuroma for Subjects significant the discontinued in lack surgery standard to QX of treatment treatment Nerve the ankle period, from this the indicative is for this of X ongoing, top study we
life growing X area from comprehensive repair. This with while to extension peripheral high-quality products our other neuromas The caps meaningful clear, the is subjects pilot foundation clinically concluded a in authors foot, and is believe addition, had population the with enrolling. AxoGuard of data solid applicability showed we is study of Nerve publications areas has body. Marketing currently the all diameter our our nerve study Caps neuromas Also REPOSE-XL. we clinical meaningful X large procedure study Nerve of significant line collection for of diameters in Cap, further with that most the study evidence quality initiated measures. called and new nerve This priority, focuses a of of AxoGuard a on in improvements the In for the millimeters. in that a
safety, portfolio evidence adoption the performance among clinical we solutions full algorithm of the XXX nerve products. of continued repair As applications, utility demonstrate of AxoGen peer-reviewed and numbers surgical our nerve the the all across the including of the end papers now repair breast, support committed trauma, our of to have We pain. of quarter, OMF remain to developing with to repair nerve growing the and treatment our
year Moving in revenue XXXX, XX% million. on guidance to our Full range expect excluding margin we of expected $XXX to the full be gross is still the represents Avive This revenue revenue growth be that in to continue XX%. full guidance, will $XXX million year XXXX XX% over from year. last to year above to
procedure XXXX, but we call, to outlook more and rates growth As growth in year our in being revenue to a for compared we second are improvements the year. our of in return normalized of we in first the noted the the February half anticipate volume half the measured
Our us built evidence organization the abate. year of is this allow confident initial a right and with sustainable solid meeting expectations, as we're will long-term impact clinical progress deliver our to growth pandemic that that of foundation we've the the
to delivering XX% We long-term low continue growth high AxoGen range. sustainable view annual as revenue the to growth teens in company, a
for the to highlights. a Now, call I'll Pete of financial review turn over Pete?
